|
|
|
23.06.25 - 14:03
|
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appointed as a member of the Nominating and Corporate Governance Committee of the Board. The company's lead product candidate RPT904, is a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E (“IgE”), a key driver of several allergic diseases. RPT904 is currently completing Phase 2 trials in chronic spontaneous urticaria and asthma, and RAPT plans to initiate a Phase 2 clinical trial for food allergy later this year....
|
|
|
|
|
16.06.25 - 19:57
|
XFRA: Deletion of Instruments from Boerse Frankfurt - 16.06.2025 (XETRA)
|
|
|
The following instruments on Boerse Frankfurt do have their last trading day on 16.06.2025
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.06.2025
ISIN Name
GB00BLNNFY18 HARMONY ENERGY INCOME TR.
LU0039632921 UNIRENTACORP INH. A
LU0055734320 UNIRESERVE: EURO A
LU0059863547 UNIRESERVE: USD
LU0192293511 UNIEURORENTA REAL ZINS A
LU0192294089 UNIEURORENTA REAL -NET-A
LU0247467987 UNIRESERVE:EO-CORPORATES
NL0012170237 PLAYA HOTELS+RES. EO -,10
SE0014855292 READLY INTERNATIONAL AB
US23344D1081 DADA NEXUS LTD ADS
US31572Q8087 FIBROGEN INC. DL-,01
US3498531017 FORWARD AIR CORP. DL-,01
US75382E1091 RAPT THERAP. INC.DL-,0001
US81728A1088 SENSEI BIOTHER. DL -,0001...
|
|
|
16.06.25 - 16:42
|
XFRA: ISIN Change (XETRA)
|
|
|
Einstellung Aufnahme
ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen
US31572Q8087 FibroGen Inc. 16.06.2025 US31572Q8814 FibroGen Inc. 17.06.2025 Tausch 25:1
US75382E1091 Rapt Therapeutics Inc. 16.06.2025 US75382E2081 Rapt Therapeutics Inc. 17.06.2025 Tausch 8:1
US81728A1088 Sensei Biotherapeutics Inc. 16.06.2025 US81728A2078 Sensei Biotherapeutics Inc. 17.06.2025 Tausch 20:1
US3498531017 Forward Air Corp. 16.06.2025 US34986A1043 Forward Air Corp. 17.06.2025 Tausch 1:1...
|
|
|
13.06.25 - 15:03
|
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025....
|
|
|
04.06.25 - 22:09
|
RAPT Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in June:...
|
|
|
|
|
15.04.25 - 14:03
|
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E (“IgE”), a key driver of several allergic diseases. RAPT plans to pursue development of RPT904 initially in food allergy and chronic spontaneous urticaria (“CSU”)....
|
|
|
07.03.25 - 22:33
|
RAPT Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in March:...
|
|
|
|
|
|
|
09.01.25 - 14:03
|
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 a.m. Pacific Time....
|
|
|
06.01.25 - 14:03
|
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company′s Board of Directors (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company....
|
|
|
|
|
23.12.24 - 13:12
|
RAPT Therapeutics Announces $150 Million Private Placement (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel therapies for patients with significant unmet needs in inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 100,000,000 shares of common stock at a purchase price of $0.85 per share and (ii) to certain investors, in lieu of shares of common stock, pre-funded warrants to purchase up to 76,452,000 shares of common stock at a price per pre-funded warrant of $0.8499, for gross proceeds of approximately $150.0 million. The private placement is expected to close on or about December 27, 2024, subject to the satisfaction of customary closing conditions. The pre-funded warrants will have an exercise price of $0.0001 per share of common stock, be immediately exercisable and remain e...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
